Connect Biopharma Holdings (CNTB)
(Delayed Data from NSDQ)
$1.18 USD
+0.02 (1.72%)
Updated Nov 1, 2024 03:51 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
View All Zacks #1 Ranked Stocks
Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Price Targets
| Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
|---|---|---|---|
| $7.00 | $8.00 | $6.00 | 493.22% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Connect Biopharma Holdings Limited Sponsored ADR comes to $7.00. The forecasts range from a low of $6.00 to a high of $8.00. The average price target represents an increase of 493.22% from the last closing price of $1.18.
Analyst Price Targets (2 )
Broker Rating
Connect Biopharma Holdings Limited Sponsored ADR currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on two recommendations.
Of the two recommendations deriving the current ABR, two are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
| Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
| Date | Brokerage Firm | Analyst | Previous | Current |
|---|---|---|---|---|
| 10/7/2024 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
| 6/13/2024 | H.C. Wainwright & Co. | Emily Bodnar | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
| Current ABR | 1.00 |
| ABR (Last week) | 1.00 |
| # of Recs in ABR | 2 |
| Average Target Price | $7.00 |
| LT Growth Rate | NA |
| Industry | Medical - Biomedical and Genetics |
| Industry Rank by ABR | 89 of 252 |
| Current Quarter EPS Est: | NA |
CNTB FAQs
Connect Biopharma Holdings Limited Sponsored ADR (CNTB) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 2 brokerage firms.
The average price target for Connect Biopharma Holdings Limited Sponsored ADR (CNTB) is $7.00. The current on short-term price targets is based on 1 reports.
The forecasts for Connect Biopharma Holdings Limited Sponsored ADR (CNTB) range from a low of $6 to a high of $8. The average price target represents a increase of $493.22 from the last closing price of $1.18.
The current UPSIDE for Connect Biopharma Holdings Limited Sponsored ADR (CNTB) is 493.22%
Based on short-term price targets offered by two analysts, the average price target for Connect Biopharma Holdings Limited Sponsored ADR comes to $7.00. The forecasts range from a low of $6.00 to a high of $8.00. The average price target represents an increase of 493.22% from the last closing price of $1.18.